Organon adds Eli Lil­ly mi­graine meds to wom­en's health port­fo­lio in Eu­rope

Mer­ck spin­off Organon is adding two Eli Lil­ly mi­graine treat­ments to its Eu­ro­pean port­fo­lio as it con­tin­ues to look for new of­fer­ings to fill out its women’s health port­fo­lio.

The com­pa­ny is in­ter­est­ed in “any­thing that is dis­pro­por­tion­ate­ly af­fect­ing the health of women,” re­gion­al pres­i­dent of com­mer­cial in Eu­rope and Cana­da Nico van Hoecke told End­points News on Mon­day. Lil­ly’s Em­gal­i­ty (gal­canezum­ab) and Reyvow (las­mid­i­tan) fit that bill, as mi­graine is three times more com­mon in women than men. Organon has agreed to shell out $50 mil­lion up­front for the com­mer­cial rights in Eu­rope, in ad­di­tion to sales-based mile­stones.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER